Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study

Basit Öğe Kaydı
dc.contributor.authorÖztop, İlhan
dc.contributor.authorÖzkan, Metin
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorDane, Faysal
dc.contributor.authorUncu, Doğan
dc.contributor.authorElkıran, Emin
dc.contributor.authorÖksüzoğlu, Ömür
dc.date.accessioned2024-04-24T19:11:48Z
dc.date.available2024-04-24T19:11:48Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: The study aimed to evaluate the efficacy of targeted therapies used as the third-line treatment after first-line cytokineand second-line tyrosine kinase inhibitor (TKI) therapies in metastatic renal cell carcinoma (mRCC) patients and assess the quality of life (QoL)of patients. Material and Methods: This national, multicenter, non-interventional study included patients aged ?18 years with histologicallyconfirmed mRCC, receiving targeted therapies as the third-line treatment for the last one month. Overall survival (OS), progression-free survival (PFS), adverse events (AEs), and QoL were evaluated. Results: The study included 102 mRCC patients (74 males) (median age of 61years). The median disease duration since diagnosis was 27.5 months (ranging 4-201 months). Of all the patients, 75.5% and 24.5% were receiving Axitinib and Everolimus, respectively, as third-line therapy. In all patients, the one-year PFS and OS rates were 62.9% and 79.9%,respectively. Seventy-one AEs (mostly mild) developed in 29 (28.4%) patients, fatigue being the most common (9.8%) AE. As compared tothe baseline, no significant change was observed in the QoL scores of patients in the 12th month. The Axitinib and Everolimus groups did notdiffer significantly as regards to PFS and OS. Of the 11 patients with grade III-IV AEs, four were from the Everolimus group, and seven belonged to the Axitinib group. The QoL scores did not show a significant difference between the two groups except for that in the 12th month.Conclusion: Third-line therapy in mRCC patients was found to be effective and tolerable. Prolonged survival in mRCC patients receiving anincreasing number of therapy lines requires further evaluation of QoL, considering it to be a part of treatment assessment.en_US
dc.identifier.doi10.37047/jos.2020-75080
dc.identifier.endpage95en_US
dc.identifier.issn2651-4532
dc.identifier.issue2en_US
dc.identifier.startpage87en_US
dc.identifier.trdizinid355190
dc.identifier.urihttps://doi.org/10.37047/jos.2020-75080
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/355190
dc.identifier.urihttps://hdl.handle.net/11468/28202
dc.identifier.volume6en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofJournal of oncological sciences
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleThird-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Studyen_US
dc.titleThird-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu